COVID-19：富士フイルム、クウェートでアビガン治験へ：関係者筋（動画）：
COVID-19: FUJIFILM to Kuwait Avegan Trial: The sources said：
消息来源：COVID-19：FUJIFILM到科威特Avegan的审判
COVID-19：
富士フイルムホールディングス：
7月18日、富士フイルム提携先のインドDr. Reddy’s Laboratoriesが、
「COVID-19治療薬・アビガンの臨床試験（治験）を、7月中にクウェートで始める」と明らかにしました。
クウェートで、最大千人程度の治験を実施し、効果を確認します。
クウェートでの治験：
富士フイルムは、「インド大手製薬会社Dr. Reddy’s Laboratoriesに、海外での開発権などを独占的に付与」しており、Dr. Reddy’s主体で実施するとのこと。
米ジョンズ・ホプキンズ大：
集計によると、クウェートの累計の感染者は5万8千人を超えている。
クウェートで有効なデータが得られれば、日本で活用する可能性がある。
共同通信
https://this.kiji.is/657040464651830369
Fujifilm to start clinical study of COVID-19 drug Avigan in Kuwait
Fujifilm Holdings Corp.
will start a clinical study of the antiviral drug Avigan in Kuwait as early as this month in collaboration with an Indian partner company, sources close to the matter said Saturday.
India’s Dr. Reddy’s Laboratories Ltd.
is expected to mainly conduct the clinical study involving up to 1,000 people to assess its effectiveness, according to the sources.
Earlier this month, Fujifilm
said it had granted exclusive rights to Dr. Reddy’s to develop, produce and sell the potential COVID-19 treatment drug overseas, along with Dubai-based Global Response Aid.
Avigan
has been seen as a possible treatment for the COVID-19 respiratory disease caused by the novel coronavirus.
Fujifilm Toyama Chemical Co., the Japanese firm’s subsidiary that developed Avigan,
also known as favipiravir, was initially planning to conduct its clinical study targeting 96 people in Japan from late March through the end of June.
But the trial did not proceed in accordance with the plan as the number of infections in Japan was dwindling some weeks during the period.
The number of COVID-19 infections in Kuwait was more than 58,200 as of Saturday, while that of Japan came to some 24,100, according to a tally by Johns Hopkins University.
The sources said if effective data were collected during the study in Kuwait, they could be used in Japan.
Earlier this month, Fujita Health University, which has led a team carrying out clinical tests of Avigan, said again its study failed to demonstrate a clear efficacy in treating coronavirus patients at an early stage of the disease.
Dr. Reddy’s partners with FUJIFILM and Global Response Aid for Avigan® (favipiravir), a potential treatment of COVID-19
https://www.drreddys.com/media/904732/press-release_dr-reddys-avigan.pdf